Atogepant (Qulipta)

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses atogepant (Qulipta), 10 mg, 30 mg, and 60 mg, oral tablets. Indication: The prevention of episodic migraine (< 15 migraine days per month) in adults.